Indeed, piperlongumine activated NRF2 in CTOSs but not in fibroblasts, suggesting that GSTπ inhibition is more detrimental against cancer cells due to GSTP1 up‐regulation (Figs. 1, S5 and S6). The gene discussed is GSTP1; the disease is cancer.